CG Oncology (CGON) Long-Term Deferred Tax (2023)

CG Oncology (CGON) posted Long-Term Deferred Tax of $4.7 million for Q4 2023.

CG Oncology (CGON) Long-Term Deferred Tax (2023) Analysis & Trends

CG Oncology's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $4.7 million for Q4 2023.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $4.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.7 million (changed N/A YoY) and the FY2023 annual result came in at $4.7 million, changed N/A from the prior year.
Long-Term Deferred Tax was $4.7 million for Q4 2023 at CG Oncology.
Across five years, Long-Term Deferred Tax topped out at $4.7 million in Q4 2023 and bottomed at $4.7 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	CG Oncology	5.86 Bn	5.86 Bn	-1.88 Mn

Download Data

Date	Value
Dec 31, 2023	4.67 Mn